Provectus News Provectus Biopharmaceuticals' A
Post# of 22756
Posted On: 03/16/2015 9:27:54 AM
Provectus News
Provectus Biopharmaceuticals' Amended Protocol of PV-10 for Phase 3 Study as Treatment for Melanoma Now Available Online
Study Timeline Remains Unchanged, IRB Approval Process Begun
Minor Changes to Patient Eligibility, Endpoint Assessment and Crossover of Patients
Monday March 16, 2015
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that the amended protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available at: http://clinicaltrials.gov/ct2/show/study/NCT02288897. The Company does not require additional review from the U.S. Food and Drug Administration(the "FDA" to start the phase 3 study, and has begun the process of gaining approval from the Institutional Review Board (IRB) of each individual site for the amended protocol.
Minor changes to the protocol affect patient eligibility, endpoint assessment and late crossover of patients. Specifically, the protocol has changed upon the advice of the FDA in the following ways:
V600 wild-type patients rather than BRAF V600E wild-type patients may be enrolled, thereby excluding a small fraction of melanoma patients with the BRAF V600K mutation;
Eligible subjects will be required to have 1-5 target lesions having a maximum diameter of at least 10 mm per lesion (vs. 2-5 target lesions each having a maximum diameter of 5 mm);
The previous secondary endpoint of "change in total symptom score from baseline using the patient reported Skindex-16 instrument (to be assessed 12 weeks after Day 1)" has been re-assigned exploratory endpoint status; and
late crossover of patients at the end of the study has been eliminated and "clinically significant progression" has been eliminated from the definition of progression.
The Company amended its phase 3 protocol following a Type C meeting with the FDA to review certain operational aspects of the protocol. The meeting was held by teleconference on January 29, 2015. Topics formally reviewed included subject eligibility requirements, primary and secondary study end points, and study lesion definitions and conventions for defining disease progression. The outcome of the review does not affect the fundamental design of the study nor the patient population.
The amended protocol states that the study is "an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy with dacarbazine (DTIC) or temozolomide (TMZ) to assess treatment of locally advanced cutaneous melanoma in patients who are BRAF V600 wild-type and have failed at least one immune checkpoint inhibitor or are not otherwise candidates for an immune checkpoint inhibitor. Subjects in the comparator arm will receive the Investigator's choice of dacarbazine or temozolomide as determined by Investigator preference and/or local availability of the agent. Effectiveness will be assessed by comparison of progression-free survival (PFS) between all intent-to-treat (ITT) subjects in the two study treatment arms."
As a result of the FDA review, the protocol has been amended from enrolling BRAF V600E wild-type patients to V600 wild-type patients, thereby excluding a small fraction of melanoma patients with the BRAF V600K mutation. The protocol was also amended to require failure of a single immune checkpoint inhibitor (vs. previous eligibility requiring failure of ipilimumab or another immune checkpoint inhibitor). Eligible subjects will be required to have 1-5 target lesions having a maximum diameter of at least 10 mm per lesion (vs. 2-5 target lesions each having a maximum diameter of 5 mm); this change brings the definition of target lesions into full conformity with RECIST 1.1.
The Primary Outcome Measure is progression-free survival (PFS) to be assessed every 12 weeks up to 18 months.
The Secondary Outcome Measures include complete response rate (CRR) and its duration (to be assessed every 12 weeks up to 18 months); Overall survival (OS) to be assessed every 12 weeks up to 18 months; and number of participants with adverse events assessed every 4 weeks until 28 days after last treatment. Safety and tolerability will be assessed by monitoring the frequency, duration, severity and attribution of adverse events and evaluating changes in laboratory values and vital signs. The previous secondary endpoint of "change in total symptom score from baseline using the patient reported Skindex-16 instrument (to be assessed 12 weeks after Day 1)" has been re-assigned exploratory endpoint status; this may change once the Company completes an ongoing assessment of the suitability of the Skindex-16 instrument for this patient population.
Finally, based on advice from FDA, late crossover of patients at the end of the study has been eliminated and "clinically significant progression" has been eliminated from the definition of progression. The latter change brings the definition of progression into tighter conformance with RECIST 1.1 criteria, while the former change removes the possibility that crossover of patients at the end of the study who have not already progressed on the comparator arm could detrimentally impact secondary endpoints.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140316.1 on the Provectus website.
Provectus Biopharmaceuticals' Amended Protocol of PV-10 for Phase 3 Study as Treatment for Melanoma Now Available Online
Study Timeline Remains Unchanged, IRB Approval Process Begun
Minor Changes to Patient Eligibility, Endpoint Assessment and Crossover of Patients
Monday March 16, 2015
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that the amended protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available at: http://clinicaltrials.gov/ct2/show/study/NCT02288897. The Company does not require additional review from the U.S. Food and Drug Administration(the "FDA" to start the phase 3 study, and has begun the process of gaining approval from the Institutional Review Board (IRB) of each individual site for the amended protocol. Minor changes to the protocol affect patient eligibility, endpoint assessment and late crossover of patients. Specifically, the protocol has changed upon the advice of the FDA in the following ways:
V600 wild-type patients rather than BRAF V600E wild-type patients may be enrolled, thereby excluding a small fraction of melanoma patients with the BRAF V600K mutation;
Eligible subjects will be required to have 1-5 target lesions having a maximum diameter of at least 10 mm per lesion (vs. 2-5 target lesions each having a maximum diameter of 5 mm);
The previous secondary endpoint of "change in total symptom score from baseline using the patient reported Skindex-16 instrument (to be assessed 12 weeks after Day 1)" has been re-assigned exploratory endpoint status; and
late crossover of patients at the end of the study has been eliminated and "clinically significant progression" has been eliminated from the definition of progression.
The Company amended its phase 3 protocol following a Type C meeting with the FDA to review certain operational aspects of the protocol. The meeting was held by teleconference on January 29, 2015. Topics formally reviewed included subject eligibility requirements, primary and secondary study end points, and study lesion definitions and conventions for defining disease progression. The outcome of the review does not affect the fundamental design of the study nor the patient population.
The amended protocol states that the study is "an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy with dacarbazine (DTIC) or temozolomide (TMZ) to assess treatment of locally advanced cutaneous melanoma in patients who are BRAF V600 wild-type and have failed at least one immune checkpoint inhibitor or are not otherwise candidates for an immune checkpoint inhibitor. Subjects in the comparator arm will receive the Investigator's choice of dacarbazine or temozolomide as determined by Investigator preference and/or local availability of the agent. Effectiveness will be assessed by comparison of progression-free survival (PFS) between all intent-to-treat (ITT) subjects in the two study treatment arms."
As a result of the FDA review, the protocol has been amended from enrolling BRAF V600E wild-type patients to V600 wild-type patients, thereby excluding a small fraction of melanoma patients with the BRAF V600K mutation. The protocol was also amended to require failure of a single immune checkpoint inhibitor (vs. previous eligibility requiring failure of ipilimumab or another immune checkpoint inhibitor). Eligible subjects will be required to have 1-5 target lesions having a maximum diameter of at least 10 mm per lesion (vs. 2-5 target lesions each having a maximum diameter of 5 mm); this change brings the definition of target lesions into full conformity with RECIST 1.1.
The Primary Outcome Measure is progression-free survival (PFS) to be assessed every 12 weeks up to 18 months.
The Secondary Outcome Measures include complete response rate (CRR) and its duration (to be assessed every 12 weeks up to 18 months); Overall survival (OS) to be assessed every 12 weeks up to 18 months; and number of participants with adverse events assessed every 4 weeks until 28 days after last treatment. Safety and tolerability will be assessed by monitoring the frequency, duration, severity and attribution of adverse events and evaluating changes in laboratory values and vital signs. The previous secondary endpoint of "change in total symptom score from baseline using the patient reported Skindex-16 instrument (to be assessed 12 weeks after Day 1)" has been re-assigned exploratory endpoint status; this may change once the Company completes an ongoing assessment of the suitability of the Skindex-16 instrument for this patient population.
Finally, based on advice from FDA, late crossover of patients at the end of the study has been eliminated and "clinically significant progression" has been eliminated from the definition of progression. The latter change brings the definition of progression into tighter conformance with RECIST 1.1 criteria, while the former change removes the possibility that crossover of patients at the end of the study who have not already progressed on the comparator arm could detrimentally impact secondary endpoints.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140316.1 on the Provectus website.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼